RMD Open

Sex and anticitrullinated protein antibodies modify the relationship between inflammation and cardiovascular risk in rheumatoid arthritis

Objectives Female sex and anticitrullinated protein antibodies (ACPA) are associated with higher disease activity in ...
rmdopen.bmj

Guselkumab provides durable improvement across psoriatic arthritis disease domains: post hoc analysis of a phase 3, randomised, double-blind, placebo-controlled study

Objective Evaluate long-term guselkumab effectiveness across Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA)-recognised domains/related conditions of psoriatic ...
rmdopen.bmj

Diffuse idiopathic skeletal hyperostosis (DISH): where we are now and where to go next

Diffuse idiopathic skeletal hyperostosis (DISH) is a well-recognised entity characterised by calcifications and ossifications of the entheses affecting mainly the spine and peripheral sites. DISH is ...
rmdopen.bmj

Transition phase towards psoriatic arthritis: clinical and ultrasonographic characterisation of psoriatic arthralgia

Objective Non-specific musculoskeletal pain is common in subjects destined to develop psoriatic arthritis (PsA). We evaluated psoriatic patients with arthralgia (PsOAr) compared with psoriasis alone ...
rmdopen.bmj

Impact of clinical domains other than arthritis on composite outcomes in psoriatic arthritis: comparison of treatment effects in the SEAM-PsA trial

Objective We used the Study of Etanercept And Methotrexate in Combination or as Monotherapy in Subjects with Psoriatic Arthritis (SEAM-PsA) data set to examine the impact of presence of enthesitis, ...
rmdopen.bmj

Do high rheumatoid factor levels impact response to certolizumab pegol in patients with inadequately controlled rheumatoid arthritis? A post hoc analysis of the phase IIIb ...

Objectives To assess the impact of rheumatoid factor (RF) levels and previous inadequate responses/intolerance to tumour necrosis factor inhibitors (TNFi-IR) on the efficacy of certolizumab pegol (CZP ...
rmdopen.bmj

Defining criteria for disease activity states in juvenile dermatomyositis based on the Juvenile Dermatomyositis Activity Index

Objectives To develop and validate the cut-offs in the Juvenile DermatoMyositis Activity Index (JDMAI) to distinguish the states of inactive disease (ID), low disease activity (LDA), moderate disease ...
rmdopen.bmj

Patterns of spinal new bone formation in patients with axial spondyloarthritis, psoriatic arthritis, rheumatoid arthritis and healthy controls: a low-dose CT study

Objective This study (the SpACT study) aimed to investigate the frequency and localisations of different types of spinal new bone formation (NBF) in patients with axial spondyloarthritis (axSpA), ...
rmdopen.bmj

RA-risk synovium exhibits DNA damage coupled with impaired DNA repair in fibroblasts

Objectives Understanding the molecular changes in the preclinical synovium is crucial for identifying factors that drive arthritis development. Persistent DNA damage in tissues is known to drive a ...
rmdopen.bmj

Strengths and limitations of the EULAR definition for difficult-to-treat rheumatoid arthritis

The management of rheumatoid arthritis (RA) has significantly improved, but a substantial number of patients still experience persistent disease activity, leading to the concept of ‘difficult-to-treat ...
rmdopen.bmj

Comparative effectiveness and persistence of ixekizumab and other b/tsDMARDs in patients with PsA from a real-world setting: 12-month results from the PRO-SPIRIT study

Objectives This prespecified interim analysis of the PRO-SPIRIT observational study compares the effectiveness and persistence of ixekizumab (IXE) with other biologic or targeted synthetic ...